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Inotropic Contractile Reserve Can Risk-Stratify
Patients With HIV Cardiomyopathy
A Dobutamine Stress Echocardiography Study
Omar Wever-Pinzon, MD,* Sripal Bangalore, MD, MHA,† Jorge Romero, MD,*
Jorge Silva Enciso, MD,* Farooq A. Chaudhry, MD*
New York, New York
O B J E C T I V E S The purpose of this study was to assess whether inotropic contractile reserve (ICR)
during dobutamine stress echocardiography (DSE) could risk-stratify patients with human immunode-
ﬁciency virus (HIV) cardiomyopathy and predict improvement of left ventricular ejection fraction (LVEF).
B A C KG ROUND HIV cardiomyopathy is an important cause of heart failure and death. ICR is
associated with better survival and improvement of LVEF in patients with ischemic and nonischemic
cardiomyopathies. However, the prognostic value of ICR in patients with HIV cardiomyopathy is
unknown.
METHOD S Patients with HIV cardiomyopathy and a LVEF 45% who were referred for DSE were
enrolled. ICR was evaluated by the delta wall motion score index (∆WMSI), calculated as the difference
between rest and peak WMSI. Patients were followed for cardiac death and change in LVEF on follow-up.
R E S U L T S Sixty patients (75% men; age, 54  9 years) with HIV cardiomyopathy (mean LVEF, 28 
11%) formed the study group. After 2.4 2.1 years, 11 cardiac deaths occurred (event rate of 7.6%/year).
A receiver-operating characteristic curve identiﬁed a ∆WMSI of 0.38 as an optimal cut point for the
presence of ICR, with a speciﬁcity of 88% and a sensitivity of 73% for the prediction of cardiac death. On
univariable analysis, the absence of ICR (hazard ratio: 6.6; 95% conﬁdence interval: 1.93 to 22.62; p 
0.003) and New York Heart Association functional class IV (hazard ratio: 7.2; 95% conﬁdence interval: 2.20
to 23.65; p  0.001) were the only predictors of cardiac death. After 2.1  1.8 years, 41 patients had a
follow-up echocardiogram. LVEF improvement from baseline occurred in 23 patients (56%), more so in
patients with ICR than without ICR. A ∆WMSI of 0.59 predicted improvement in the LVEF with a
speciﬁcity of 78% and a sensitivity of 74%.
CONC L U S I O N S The presence of ICR during DSE can risk-stratify and predict subsequent
improvement in LVEF in patients with HIV cardiomyopathy. (J Am Coll Cardiol Img 2011;4:1231–8)
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1232uman immunodeficiency virus (HIV) car-
diomyopathy is an important cause of heart
failure and death. The incidence of HIV
cardiomyopathy before the introduction of
ighly active antiretroviral therapy (HAART) was
stimated at 15.9 per 1,000 annually (1). After the
ntroduction of HAART, the prevalence of HIV
ardiomyopathy decreased about 30% in developed
ountries (2,3). However, the access to HAART is
imited, and the prognosis of those patients in
hom HIV cardiomyopathy develops remains poor,
ith a median survival in acquired immunodefi-
iency syndrome (AIDS)–related death of 101 days
n patients with left ventricular (LV) dysfunction
nd 472 days in patients with normal LV function
t similar infection stage (4). Furthermore, patients
with HIV cardiomyopathy had worse sur-
vival when compared with all other causes
of dilated cardiomyopathy (ischemic and
nonischemic) (adjusted hazard ratio [HR]:
5.86; 95% confidence interval [CI]: 3.92
to 8.77) (5).
Recent data suggest that the use of
aggressive interventions such as ventricular
assist devices and heart transplantation in
patients with HIV may have a good out-
come in selected patients (6,7). Hence, the
ability to identify patients with HIV cardio-
myopathy at high risk of cardiac death and
who may benefit from early aggressive ther-
apy and referral for specialized care would
have important prognostic implications.
Dobutamine stress echocardiography
(DSE) is clinically useful for distinguish-
ing viable myocardium from scar in both
ischemic and nonischemic cardiomyopa-
thy. The presence of inotropic contractile
eserve (ICR) is associated with better survival,
mprovement in regional and global LV function on
ollow-up, and better response to therapy (8–10).
owever, whether ICR can risk-stratify and predict
eft ventricular ejection fraction (LVEF) improve-
ent in patients with HIV cardiomyopathy is not
nown.
M E T H O D S
Study population. We identified 76 consecutive pa-
ients with a known diagnosis of HIV/AIDS and a
VEF 45%, referred to our laboratory for clini-
ally indicated DSE from April 2004 through
anuary 2009. Prospective follow-up was performed
e
ency
ion
dexn all patients. Patients with a history of hemodynam- Tcally significant valvular abnormalities, long-standing
r uncontrolled hypertension, known etiology of car-
iomyopathy other than HIV, hemodynamic instabil-
ty, poor acoustic windows (13 of 16 segments
isualized by echocardiography), inability to give in-
ormed consent, myocardial infarction, revasculariza-
ion or hemodynamically significant coronary artery
isease as defined by50% stenosis of the left main
oronary artery, 70% stenosis of the proximal left
nterior descending artery, or70% stenosis of 2 or
ore epicardial vessels were excluded from the
tudy (n  16). Hemodynamically significant cor-
nary artery disease was excluded in all patients by
eans of coronary angiography performed any time
ithin 5 years before study enrollment. Informed
ritten consent was obtained from all patients, and
he study was approved by St. Luke’s-Roosevelt
ospital Center institutional review board. Clinical
haracteristics, medication regimen, and indications
or testing were recorded at the time of DSE.
DSE protocol. Dobutamine was administered intra-
venously beginning at a dose of 5 to 10 g/kg/min
nd increased by 5 to 10 g/kg every 3 min up to a
maximum of 50 g/kg/min or until a study end-
oint was achieved. The endpoints for termination
f the dobutamine infusion included development
f new segmental wall-motion abnormalities, at-
ainment of 85% maximum predicted heart rate,
nd the development of significant adverse effects
elated to the dobutamine infusion. Atropine was
dministered intravenously in 0.25-mg increments
very 3 min up to a maximum of 2.0 mg if a study
ndpoint was not achieved at the maximum dobut-
mine dose (11).
Beta-blockers were held on the morning of the
SE study. Using commercially available ultra-
ound equipment, 7 standard echocardiographic
iews were obtained with each acquisition: apical
-chamber, apical 3-chamber, apical 2-chamber,
arasternal long-axis, parasternal short-axis, sub-
ostal short-axis, and subcostal 4-chamber views.
ll images were acquired within 60 s, and the entire
equence was repeated again to acquire a second run
f images. Echocardiographic images were acquired
t baseline, with each increment of dobutamine
nfusion, and during the recovery phase. Cardiac
hythm, 12-lead electrocardiograms, and blood
ressure were monitored throughout the study.
Echocardiographic image analysis. Regional wall
otion analysis was performed by an experienced
chocardiographer blinded to the patient’s demo-
raphic, clinical, and echocardiography outcomes.A B B R E V I A T I O N S
A N D A C R O N YM S
AIDS acquired
immunodeficiency syndrom
CI confidence interval
DSE dobutamine stress
echocardiography
HAART highly active
antiretroviral therapy
HIV human immunodefici
virus
HR hazard ratio
ICR inotropic contractile
reserve
LV left ventricular
LVEF left ventricular eject
fraction
RV right ventricularhe left ventricle was divided into 16 segments and
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1233a score assigned to each segment at baseline, at each
stage of stress, and during the recovery phase (12).
Each segment was scored as follows: 1  normal;
2  mild to moderate hypokinesis (reduced wall
hickening and excursion); 3  severe hypokinesis
marked reduced wall thickening and excursion);
 akinesis (no wall thickening and excursion);
 dyskinesis (paradoxical wall motion away from
he center of the left ventricle during systole) (8). A
V wall motion score index (WMSI) during each
tage was derived from the cumulative sum score of
6 LV wall segments divided by the number of
isualized segments. The right ventricle was divided
nto 3 segments: apical, mid, and basal. Each
egment was scored on a 1- to 5-point scale similar
o the LV wall motion scale. A resting right
entricular (RV) WMSI was calculated as the
umulative sum score of the 3 segments divided by
he number of visualized RV segments (11).
LV volume and ejection fraction assessment. Assess-
ment of LV volumes and LVEF was performed
using the apical 4- and 2-chamber views. The
endocardial border at both end-systole and end-
diastole was manually traced; and LV end-systolic
volume, end-diastolic volume, and LVEF were
determined using the biplane modified Simpson
formula (13).
Inotropic contractile reserve. An LV segment was
considered to have contractile reserve when it im-
proved by at least 1 grade at peak stress (e.g., a
hypokinetic segment becoming normal or an aki-
netic segment becoming hypokinetic). To quantify
the amount of myocardium showing contractile
reserve elicited by dobutamine, ICR was assessed
according to a continuous parameter defined as
WMSI, which expresses the difference between
rest and peak dose WMSI. This parameter provides
information on the presence and extent of contrac-
tile reserve of dysfunctional myocardium. The pres-
ence of ICR was defined by cut point values of
WMSI that predicted with the highest accuracy car-
diac death and subsequent LVEF improvement. The
optimalWMSI cut point values were determined using
eceiver-operating characteristic curves.
Patient follow-up. Serial prospective follow-up (mean
.4  2.1 years) was performed in all patients by
eans of a physician-directed telephone interview
sing a standardized questionnaire. The physicians
nvolved in the patient’s follow-up were blinded to the
atient’s clinical and echocardiography data. If the
atient died during follow-up, the closest surviving
elative and the patient’s physician were interviewed
o determine the cause of death. The primaryutcome of the study was cardiac death. The
efinition of cardiac death required the following:
ocumentation of significant arrhythmias or cardiac
rrest or both, or death attributable to congestive
eart failure or myocardial infarction in the absence
f any other precipitating factors. Cardiac death
as confirmed by review of the hospital medical
ecord and/or death certificate. In case of death out
f hospital, sudden unexpected death was attributed
o a cardiac cause. Adjudication of cardiac death
as done by physicians who were blinded to the
linical and stress echocardiographic data. Subjects
ho died of noncardiac causes were censored at date
f death. A secondary outcome was to determine
he change in LVEF on subsequent echocardio-
rams and correlate LVEF improvement (5%
ncrease) with the presence of ICR.
Statistical analysis. All analyses were carried out
sing a standard statistical software package (SPSS
or Windows, Version 16.0, SPSS Inc., Chicago,
llinois). Data were summarized using standard
tatistical descriptors such as means, medians, SDs,
ercentiles, frequencies, and percentages. Patient
roups were compared using the 2-sample Student
test for normally distributed continuous variables
nd Wilcoxon rank sum test for others. The Fisher
xact test was used to compare categorical variables.
eceiver-operator characteristic curves were con-
tructed to assess the accuracy of WMSI to
redict cardiac death and subsequent LVEF im-
rovement. The optimal cut point values from the
eceiver-operator characteristic curves were chosen
y use of the Youden index. A univariable Cox
roportional hazard model was used to identify
redictors of cardiac death. Nonparametrically dis-
ributed variables were examined after logarithmic
ransformation was performed. Cumulative survival
ates as a function of time after DSE were gener-
ted using Kaplan-Meier survival analysis and com-
ared using log rank analysis. A p value 0.05 was
onsidered to be significant. Because of the risk of
ortality due to noncardiac causes as a competing
utcome with cardiac death, a competing-risks
urvival regression analysis and an all-cause mortal-
ty analysis were performed.
R E S U L T S
Patient characteristics. A total of 60 consecutive
patients (75% men; age 54 9 years) with HIV and
LV dysfunction (mean LVEF 28  11%) met the
inclusion criteria. Indications for DSE were chest
pain (45%), dyspnea/heart failure (37%), pre-
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1234operative evaluation (8%), and other (10%). No
significant adverse events occurred during the stress
studies. Only 1 patient had a biphasic response during
DSE, and no other patient had ischemia on DSE. A
subsequent coronary angiogram revealed no evidence of
coronary artery disease in this patient. The patient’s
demographic data are shown in Table 1. Among clin-
ical characteristics, there was a high prevalence of
cardiovascular risk factors, and most patients were
at New York Heart Association functional class II
and III at the time of testing. Patients carried a
diagnosis of HIV infection for more than a decade,
and more than half of the study group had received
a diagnosis of AIDS. Accordingly, the mean CD4
Table 1. Baseline Characteristics of Patients With
HIV Cardiomyopathy
Age, yrs 54 9
Male 45 (75)
Hypertension 36 (60)
Diabetes mellitus 11 (18)
Dyslipidemia 21 (35)
NYHA functional class
I 5 (8)
II 25 (42)
III 22 (37)
IV 8 (13)
Hemodynamic variables
Resting SBP, mm Hg 128 16
Resting DBP, mm Hg 80 12
Resting heart rate, beats/min 81 12
Echocardiographic variables
Left atrial dimension index, cm/m2 2.40 0.43
LVEDVI, ml/m2 82 17
LVESVI, ml/m2 60 20
LVEF, % 28 11
Resting LV WMSI 2.59 0.57
Resting RV WMSI 1.58 0.80
∆WMSI 0.79 0.53
Medications
Beta-blocker 44 (73)
ACE-I or ARB 40 (67)
Diuretics 27 (45)
HIV-associated factors
CD4 count, cell/mm3 243 (86/348)
Viral load copies/ml 1,240 (50/36,109)
AIDS diagnosis 35 (58)
Duration of HIV infection, yrs 11 6
Antiretroviral therapy 46 (77)
Values are mean  SD, n (%), or median (25th/75th percentile).
ACE-I  angiotensin-converting enzyme inhibitor; AIDS  acquired immu-
nodeﬁciency syndrome; ARB  angiotensin II receptor blocker; DBP 
diastolic blood pressure; HIV  human immunodeﬁciency virus; LV  left
ventricular; LVEDVI  left ventricular end-diastolic volume index; LVEF  left
ventricular ejection fraction; LVESVI  left ventricular end-systolic volume
index; NYHA  New York Heart Association; RV  right ventricular; SBP 
systolic blood pressure; WMSI  wall motion score index.count was low, and the majority of patients had
increased viral loads. Among echocardiographic
variables, the left atrium and left ventricle were
enlarged, the LV systolic function was severely
impaired, and the RV function was impaired as
evidenced by an increased RV WMSI. With regard
to medication use at the time of testing, more than
two-thirds of the patients were taking beta-blockers
and angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers. Nearly one-half of
the study group was taking diuretics, and the
majority of patients were receiving antiretroviral
therapy.
Observed events. After 2.4  2.1 years, there were
1 cardiac deaths (event rate 7.6%/year). The causes
f death were worsening congestive heart failure
nd arrhythmia. Fatal or nonfatal myocardial in-
arctions were not observed. Twelve patients died of
oncardiac causes (8 due to infections) and were
ensored at the time of death. The overall survival
ate at the end of the study period was 62%.
eceiver-operating characteristic curve analysis
emonstrated a significant association between
WMSI and cardiac death. A cut point value for
WMSI of 0.38 predicted cardiac death with a
pecificity of 88% and a sensitivity of 73% (area
nder the curve  0.75, 95% CI: 0.54 to 0.97; p 
.01). Using this cut point value of WMSI, we
tratified the study group into patients with ICR
nd patients without ICR. There were no signifi-
ant differences between the groups in the presence
f cardiovascular risk factors or the use of antire-
odeling medications. The group without ICR was
ore frequently taking diuretics (75% vs. 38%, p 
.02), was less frequently receiving antiretroviral
herapy (50% vs. 83%, p  0.01), and had a
endency toward more immunosuppression. Pa-
ients without ICR had greater LV end-systolic
olume index (74  19 ml/m2 vs. 57  18 ml/m2,
p  0.008) and LV end-diastolic volume index
(92  17 ml/m2 vs. 80  16 ml/m2, p  0.02),
lower regional and global LV function (resting LV
WMSI 2.9  0.5 vs. 2.5  0.5; LVEF 20  11%
vs. 30  11%; p  0.01), and worse RV function
(resting RV WMSI 2.2  0.9 vs. 1.4  0.6, p 
0.001) compared with those patients with ICR.
Patients without ICR had a 7 times higher event
rate compared with patients who had ICR during
DSE (event rate of 24%/year vs. 3.4%/year, p 
0.0001). A Cox proportional hazard model showed
that the absence of ICR (HR: 6.6; 95% CI: 1.93 to
22.62; p 0.003) and New York Heart Association
functional class IV (HR: 7.2; 95% CI: 2.20 to 23.65;
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1235p  0.001) were predictors of cardiac death (Table 2).
The presence of ICR effectively risk-stratified pa-
tients into high-risk and low-risk groups (Fig. 1). In
a competing-risks survival regression analysis, in-
cluding mortality from cardiac and noncardiac
causes, there was consistency in both the magnitude
and direction of the effect size such that the
presence of ICR effectively risk-stratified patients
into high-risk and low-risk groups (HR: 7.6; 95%
CI: 2.4 to 24.2; p 0.001). Survival analysis for the
outcome of all-cause mortality followed a direction
similar to that of cardiovascular mortality (HR: 2.1;
95% CI: 0.9 to 5.1; p  0.08), although statistically
nonsignificant.
LVEF improvement. After 2.1  1.8 years, 41 pa-
tients had a follow-up echocardiogram. Six of the
remaining 19 patients without a follow-up echocar-
diogram died during follow-up. Significant LVEF
improvement from baseline occurred in 23 patients
(56%) (LVEF change 29  12% to 48  9%, p 
0.0001) compared with the remaining 18 patients
(44%) (LVEF change 26  12% to 24  11%, p 
0.15). The characteristics of patients with and
without LVEF improvement are shown in Table 3.
In the receiver-operator characteristic curve analy-
sis, WMSI was strongly related to LVEF im-
provement (area under the curve  0.78; 95% CI:
0.64 to 0.93; p  0.002). The value of WMSI
with the best sensitivity (74%) and specificity (78%)
was 0.59. With this cut point value, patients were
stratified into those with ICR and those without ICR.
Sixteen patients (80%) in the group with ICR had
LVEF improvement compared with 7 patients (33%)
in the group without ICR (p  0.003). In patients
with ICR, there was a significant improvement in
LVEF, from 30  11% to 44  11% (p  0.0001)
compared with patients without ICR (change in
LVEF 24  11% to 30  17%, p  0.06).
D I S C U S S I O N
To our knowledge, this is the first study evaluating
the role of ICR in the risk stratification and
prognostication of patients with HIV cardiomyop-
athy. The results of the present study show that
even though the overall survival in patients with
HIV cardiomyopathy has markedly improved in the
contemporary era of HAART compared with pre-
vious studies (4,5), cardiac death remains an impor-
tant cause of mortality in this group. Furthermore,
the presence of ICR risk-stratified these patients
into high-risk (ICR absent) and low-risk (ICR
present) groups. Although patients with ICR hadbetter survival and higher probability of subsequent
LVEF improvement, patients without ICR had
poor outcomes.
Figure 1. Cumulative Survival as a Function of the Presence of
Inotropic contractile reserve (ICR) risk-stratiﬁed patients with human
ciency virus cardiomyopathy into high-risk and low-risk groups. The
Table 2. Predictors of Cardiac Death in Patients With HIV Cardi
Variable HR 95
Clinical variables
Age, per yr 0.99 0.93–
Hypertension, yes vs. no 0.68 0.20–
Diabetes mellitus, yes vs. no 0.83 0.18–
Dyslipidemia, yes vs. no 0.64 0.17–
NYHA functional class IV vs. classes I to III 7.20 2.20–
Hemodynamic variables
Resting SBP, per mm Hg 1.01 0.97–
Resting DBP, per mm Hg 1.01 0.95–
Echocardiographic variables
LADI, per cm/m2 2.63 0.56–
LVESVI, per ml/m2 1.02 0.99–
LVEDVI, per ml/m2 1.02 0.99–
LVEF, per percentage 0.96 0.91–
Rest LV WMSI, per U 1.46 0.53–
Rest RV WMSI, per U 1.35 0.68–
ICR, absent vs. present 6.60 1.93–
HIV-associated factors
CD4 count, per cell/mm3 1.00 0.99–
Viral load, per copy/ml 1.00 1.00–
Duration of HIV infection, per year 0.99 0.89–
Values were generated using a univariable Cox proportional hazard analysis
statistical signiﬁcance. A p value 0.05 is considered signiﬁcant.
CI  conﬁdence interval; HR  hazard ratio; ICR  inotropic contractile re
dimension index; other abbreviations as in Table 1.ICR
immunodeﬁ-
number ofomyopathy
% CI p Value
1.06 0.79
2.22 0.52
3.85 0.81
2.41 0.51
23.65 0.007
1.06 0.56
1.07 0.76
12.27 0.22
1.05 0.16
1.06 0.15
1.01 0.17
4.06 0.46
2.66 0.39
22.62 0.003
1.00 0.90
1.00 0.87
1.11 0.90
. Values in bold indicate
serve; LADI  left atrialpatients at risk for each follow-up period is given below the graph.
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1236HIV infection and cardiomyopathy. Since it was first
escribed in 1986 (14), dilated cardiomyopathy has
een recognized as a late manifestation of HIV
nfection. The cause of HIV cardiomyopathy is
omplex and includes myocarditis due to HIV itself
r opportunistic pathogens, autoimmune processes,
utritional deficiencies (i.e., selenium) and cardio-
oxicity due to antiretroviral agents (15). The de-
elopment of dilated cardiomyopathy in patients
ith HIV is strongly associated with advanced
tages of the disease (e.g., low CD4 count) (4,16).
he introduction of HAART has significantly re-
uced the prevalence of HIV cardiomyopathy in
eveloped countries. However, low socioeconomic
tatus, noncompliance with HAART, and underdi-
cs of Patients With and Without LVEF Improvement
Present (n  23) Absent (n  18) p Value
51 7.5 57 11 0.06
18 (78) 11 (61) 0.31
14 (60) 12 (66) 0.99
4 (17) 5 (27) 0.70
5 (21) 8 (44) 0.18
ss
4 (17) 0 0.11
7 (30) 7 (39) 0.57
10 (43) 8 (44) 0.95
2 (9) 3 (17) 0.64
s
125 14 128 18 0.61
83 9 77 11 0.09
eats/min 78 12 86 11 0.04
iables
index, cm/m2 2.34 0.45 2.46 0.44 0.41
81 18 88 18 0.23
59.6 21 66 20 0.33
29 12 26 12 0.45
2.63 0.54 2.77 0.60 0.44
1.51 0.77 1.70 0.86 0.45
16 (70) 4 (22) 0.003
15 (65) 16 (89) 0.14
14 (60) 11 (61) 1.00
10 (43) 10 (55) 0.54
3 257 (116/394) 211 (62/329) 0.50
159 (50/6,365) 1874 (50/36,100) 0.52
ction, yrs 9 5.9 11 7.2 0.29
y 18 (78) 13 (72) 0.72
n (%) or median (25th/75th percentile). Values in bold indicate statistical
.05 is considered signiﬁcant.
s 1 and 2.gnosis of HIV infection are factors that contribute to dsustained high prevalence of dilated cardiomyopathy
n this group. Studies performed in the contemporary
ra of antiretroviral therapy found a prevalence of
ilated cardiomyopathy of 17.7% (16). In our study,
8% of the patients carried a diagnosis of AIDS.
lthough 77% of the patients were receiving antiret-
oviral therapy, the remaining 23% were not receiving
ntiretroviral therapy due to either noncompliance
n 6) or lack of criteria to start therapy. Patients with
ICR (WMSI 0.38) had a tendency toward less
immunosuppression and lower viral load and were more
frequently receiving antiretroviral therapy.
Dobutamine stress echocardiography. In heart fail-
re, the sympathetic nervous system is chronically
ctivated, causing a maladaptive down-regulation
nd decrease in 1-receptor density, ultimately de-
ermining the myocardial response to dobutamine.
his response is inversely related to the degree of
eart failure and remodeling of the left ventricle
17). Our findings are consistent with these obser-
ations, suggesting a worse degree of heart failure in
atients without ICR, as evidenced by greater LV
olumes, worse regional and global LV and RV
unction, and more frequent use of diuretics.
Prognostic value of ICR. The findings of the present
tudy are in accordance with a large body of
vidence supporting the value of ICR in the risk
tratification and prognostication of patients with
schemic and nonischemic cardiomyopathy (8–10).
imilarly, the presence of ICR further risk-stratified
atients with HIV cardiomyopathy into high-risk
ICR absent) and low-risk (ICR present) groups.
atients without ICR had a yearly event rate that
as 7 times higher than that in those with ICR.
sing a Cox proportional hazard model, the ab-
ence of ICR and a New York Heart Association
unctional class IV were significant predictors of
uture cardiac death. Other clinical and traditional
chocardiographic parameters evaluated in our
tudy were not found to be predictors of cardiac
eath, although diastolic parameters other than left
trial size were not evaluated. Resting LVEF, a
owerful predictor of future cardiovascular events in
atients with and without HIV (4,18), showed a
rend toward prediction of cardiac death; however, it
id not reach statistical significance. This lack of effect
f resting LVEF on outcomes could be related to the
imited number of events in our cohort. The absence
f ICR predicted future cardiac death with a specificity
f 88% and a sensitivity of 73%.
Prediction of LVEF improvement. To our knowledge,
his is the first study demonstrating reversibility of LVTable 3. Characteristi
LVEF Improvement
Clinical variables
Age, yrs
Men
Hypertension
Diabetes mellitus
Dyslipidemia
NYHA functional cla
I
II
III
IV
Hemodynamic variable
Resting SBP, mm Hg
Resting DBP, mm Hg
Resting heart rate, b
Echocardiographic var
Left atrial dimension
LVEDVI, ml/m2
LVESVI, ml/m2
LVEF, %
Resting LV WMSI
Resting RV WMSI
ICR present
Medications
Beta-blocker
ACE-I or ARB
Diuretics
HIV-associated factors
CD4 count, cell/mm
Viral load copies/ml
Duration of HIV infe
Antiretroviral therap
Values are mean  SD,
signiﬁcance. A p value 0ysfunction in patients with HIV cardiomyopathy. A
r
c
l
c
t
t
h
m
a
p
o
m
r
o
i
d
t
m
a
t
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1237prospective echocardiographic study conducted before
the introduction of HAART did not show LVEF
improvement in adults with HIV/AIDS and LV
dysfunction after 1 year of follow-up (19). Reversibil-
ity of LV dysfunction in an adult with HIV and acute
myocarditis has been previously reported (20), but not
in patients with chronic LV dysfunction. Our study
shows that 56% of the patients had improvement in
LVEF on follow-up, although 6 of the remaining 19
patients without a follow-up echocardiogram died,
which could potentially result in over- or underesti-
mation of the number of patients with improvement
in LVEF. The most significant difference between
both groups was the presence ICR. The exact mech-
anism of this recovery is unclear. There were no
differences between both groups in the use of antire-
modeling medications. Patients without LVEF im-
provement had a tendency toward greater left atrial
and LV size, worse LV and RV function, lower CD4
count, and longer duration of HIV infection. A
possible explanation for this functional recovery is that
patients with LVEF improvement had a less advanced
stage of the diseases (HIV and cardiomyopathy), as
evidenced by a trend toward less remodeling and
immunosuppression, with a lesser degree of down-
regulation of 1-receptors, thus allowing a greater
response to medical therapy. Interestingly, patients
without LVEF improvement had higher resting heart
rates, which may be related to a higher adrenergic drive
and thus a worse degree of cardiomyopathy.
The presence of ICR predicted subsequent
LVEF improvement with a specificity of 78% and
sensitivity of 74%.
Clinical implications. The present study is the first to
eport LVEF improvement in patients with HIV
ardiomyopathy. Although the development of di-
ated cardiomyopathy in patients with HIV is asso-
iated with poor outcomes, our results showed that
he assessment and detection of ICR by DSE inEffect of highly active antiretroviral initially unexplainigher probability of subsequent LVEF improve-
ent and better outcomes. On the other hand, the
bsence of ICR was associated with a very poor
rognosis. Therefore, patients with HIV cardiomy-
pathy without ICR may benefit from aggressive
anagement of their antiretroviral regimen, early
eferral to a center experienced in the management
f patients with end-stage HIV cardiomyopathy for
ntensification of medical therapy, or referral for
evice-based therapies (e.g., cardiac resynchronization
herapy), and in very carefully selected patients (nor-
al CD4 count, undetectable viremia, good compli-
nce, and psychosocial support), advanced heart failure
herapies might be a reasonable alternative.
Study limitations. Analysis of segmental wall motion
is subjective. Nevertheless, this is routinely used in
clinical practice for the detection of myocardial viabil-
ity and is widely accepted. Medication regimens were
only recorded at the time of testing; therefore, no
information about duration of exposure or changes in
regimen is available. Another limitation is that indexes of
diastolic dysfunction, other than left atrial size, were not
recorded. The number of events in our study group was
limited, which did not allow us to adjust our variables in
a multivariable analysis. Even though the patients in this
cohort were carefully selected, causes of LV dysfunction
other than HIV cannot be entirely excluded.
C O N C L U S I O N S
Our results show that the presence of ICR by DSE
risk-stratifies and predicts outcomes in patients
with HIV cardiomyopathy. Furthermore, the pres-
ence of ICR identifies patients with HIV cardio-
myopathy who’s LVEF will improve.
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